首页> 外文OA文献 >Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study)

【2h】

Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study)

机译：多中心观测研究在先前内分泌治疗后雌激素受体阳性晚期或复发性乳腺癌的绝经后500毫克的多中心观测研究（SBCCSG29研究）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kei Kimizuka; Kenichi Inoue; Shigenori E. Nagai; Tsuyoshi Saito; Satoko Nakano; Kazushige Futsuhara; Hirofumi Yamada; Shiori Kaneko; Takashi Sakurai; Satoshi Hata; Masafumi Kurosumi;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study) [J] . Kei Kimizuka, Kenichi Inoue, Shigenori E. Nagai, Journal of Nippon Medical School . 2019,第3期

机译：绝经后日本女性接受雌激素受体阳性晚期或复发性乳腺癌的内分泌治疗后500 mg氟韦斯特的多中心观察研究（SBCCSG29研究）
2. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy [J] . Telford Claire, Jones Nick, Livings Christopher, Clinical breast cancer . 2016,第3期

机译：网络荟萃分析比较氟维西特500 mg的总生存率与替代药物治疗绝经后，雌激素受体阳性晚期乳腺癌在先前内分泌治疗失败后的总生存率
3. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. [J] . Di Leo A, Jerusalem G, Petruzelka L, Journal of Clinical Oncology . 2010,第30期

机译：CONFIRM III期试验的结果比较了在雌激素受体阳性晚期乳腺癌的绝经后妇女中使用氟维司群250毫克和氟维司群500毫克。
4. Association of bone mineral density and mammographic breast density in premenopausal and postmenopausal Malaysian women: Study on women with and without breast cancer [C] . Norhayati Mohd Zain, Vengkatha Priya Seriramulu, Kanaga Kumari Chelliah, International Conference on Bio-engineering for Smart Technologies . 2016

机译：绝经前和绝经后马来西亚女性的骨矿物质密度与乳房X线照片乳房密度的关系：有无乳腺癌的女性研究
5. A time to question: A study of the information needs of postmenopausal breast cancer patients regarding endocrine therapy. [D] . TeBrake, Melissa Lynn. 2010

机译：问题时间：对绝经后乳腺癌患者有关内分泌治疗的信息需求的研究。
6. Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK [O] . Claire Telford, Evelina Bertranou, Samuel Large, 2019

机译：英国内分泌治疗绝经后绝经后激素受体阳性晚期乳腺癌患者中500 mg氟维西汀的成本效果分析
7. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines [O] . Lauren I. Madigan, Phuong Dinh, J. Dinny Graham 2020

机译：Neoadjuvant内分泌治疗在局部晚期雌激素或黄体酮受体阳性乳腺癌：确定绝经后妇女的最佳内分泌剂和治疗持续时间 - 是文献审查和拟议指导方针

Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study)

著录项

引文网络

相似文献

相关主题

期刊订阅